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Surveillance of circulating influenza strains for antivi-
ral susceptibility is important to ensure patient treat-
ment guidelines remain appropriate. Influenza A(H3N2) 
and A(H1N1)pdm09 virus isolates containing mutations 
at the Q136 residue of the neuraminidase (NA) that 
conferred reduced susceptibility to the NA inhibitor 
(NAI) zanamivir were detected during antiviral suscep-
tibility monitoring. Interestingly, the mutations were 
not detectable in the viruses from respective clinical 
specimens, only in the cultured isolates. We showed 
that variant viruses containing the Q136K and Q136R 
NA mutations were preferentially selected in Madin-
Darby canine kidney epithelial (MDCK) cells, but were 
less well supported in MDCK-SIAT1 cells and embryo-
nated eggs. The effect of Q136K, Q136R, Q136H and 
Q136L substitutions in NA subtypes N1 and N2 on NAI 
susceptibility and in vitro viral fitness was assessed. 
This study highlights the challenges that cell culture 
derived mutations can pose to the NAI susceptibility 
analysis and interpretation and reaffirms the need to 
sequence viruses from respective clinical specimens 
to avoid misdiagnosis. However, we also demonstrate 
that NA mutations at residue Q136 can confer reduced 
zanamivir, peramivir or laninamivir susceptibility, and 
therefore close monitoring of viruses for mutations at 
this site from patients being treated with these antivi-
rals is important.
Introduction
Neuraminidase inhibitors (NAIs) are a class of influ-
enza antivirals that target the highly conserved enzy-
matic site of the neuraminidase (NA) glycoprotein on 
the surface of influenza A and B viruses [1]. The NAIs 
have become the most widely used antivirals for the 
treatment or prophylaxis of influenza, particularly 
since the development of widespread resistance to the 
adamantanes, the older class of antivirals that block 
the M2 ion channel protein [2]. Two NAIs, oseltamivir 
and zanamivir, have been available in many countries 
since 1999, and two new NAIs, peramivir and lani-
namivir, have recently been approved for human use 
in Japan and a small number of other countries. Each 
of the NAIs is structurally different and therefore binds 
slightly differently within the NA active site [1]. This dif-
ference in binding is advantageous for treatment, as 
a virus that develops resistance against one NAI, may 
retain sensitivity to others. For example, the H275Y NA 
mutation in NA subtype N1-containing viruses confers 
resistance to oseltamivir but not to zanamivir [3].
Resistance to the NAIs commonly occurs as a result of 
amino acid mutations within the NA active site, either 
in the catalytic residues (those that interact directly 
with the NAIs), or in the framework residues (those 
that provide structural support for the catalytic resi-
dues) [4]. However, not all viruses with resistance to 
NAIs will pose a public health risk, as mutations that 
reduce binding can also impact the ability of the NA to 
interact with the natural substrate during replication 
[5]. However, in some cases, the mutation can affect 
NAI sensitivity but not compromise viral ‘fitness’. The 
H275Y mutation that was present in seasonal influenza 
A(H1N1) viruses between 2007 and 2009 is such an 
example, as it conferred oseltamivir resistance but did 
not appear to affect the ability of the virus to replicate 
and transmit [6,7].
Oseltamivir resistant influenza viruses have been 
detected at a considerably higher frequency than zan-
amivir resistant viruses. During human clinical trials, 
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oseltamivir resistance was detected in < 1–4% of adults 
[8,9] and 5–6% of treated children [10] undergoing 
oseltamivir treatment, although in observational stud-
ies the frequency of resistance in oseltamivir treated 
children has been as high as 27% [11]. Most signifi-
cantly, oseltamivir-resistant seasonal A(H1N1) viruses 
with an H275Y mutation became widespread during 
2008, spreading globally even in regions of low drug 
usage [12,13]. In comparison, there have only been a 
few reports of zanamivir resistance. The first was in 
an immunocompromised child undergoing zanami-
vir treatment where an influenza B virus with a R152K 
NA mutation was detected that caused a 40–150-fold 
reduction in zanamivir sensitivity [14,15]. More recently 
a small number of A(H1N1)pdm09 viruses with an I223R 
NA mutation have been detected in immunocompro-
mised patients exposed to oseltamivir and/or zanami-
vir [16,17] and in a patient without previous exposure 
to NAIs [18], but the change in zanamivir sensitivity as 
a result of this mutation is relatively minor (10-fold), 
compared with the larger 45-fold shift in oseltamivir 
sensitivity [16].
Previously, our group and others reported the detec-
tion of former seasonal A(H1N1) virus isolates with 
a Q136K mutation that conferred a 250-fold reduc-
tion in zanamivir sensitivity [19,20]. The Q136K iso-
lates were particularly unusual because the mutation 
could not be detected in the clinical specimens from 
which they were derived. This suggested that either 
the variant virus was being generated in cell culture or 
it was present in very low levels in the clinical speci-
men and then selectively amplified during cell culture. 
The former seasonal A(H1N1) virus stopped circulating 
soon after the emergence of the A(H1N1)pdm09 virus 
in 2009, and for the first two years after the A(H1N1)
pdm09 viruses started circulating, no Q136K variants 
were reported. However, here we report the detection 
of both Q136K and Q136R substitutions in A(H1N1)
pdm09 and A(H3N2) viruses between 2011 and 2014, 
investigate their selection in different cell lines and 
determine the effect that these and other amino substi-
tutions of the Q136 residue have on NAI susceptibility 
and NA enzymatic function.
Methods
Virus strains, Madin-Darby canine kidney 
epithelial cells and virus culture
The influenza viruses used in this study were received 
at the World Health Organization (WHO) Collaborating 
Centre for Reference and Research on Influenza 
(WHOCC), Melbourne, Australia through the WHO 
Global Influenza Surveillance and Response System 
(GISRS) from countries in the Asia Pacific region. The 
Q136K or Q136R isolates had initially been isolated 
and then passaged in MDCK cells in external laborato-
ries before being received and repassaged one to two 
further times at the WHOCC. WHOCC MDCK cells were 
originally received from ATCC (CCL-34) and used at pas-
sage level 63 to 83 and grown in Dulbecco’s modified 
Figure 1
Serial passage of A(H1N1)pdm09 influenza virus isolates 
(n=3) in different Madin-Darby canine kidney (MDCK) 
cells and embryonated hens’ eggs
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Three isolates were used, two containing a mixture of wildtype 
(WT) and variant viruses with a Q136K neuraminidase (NA) 
mutation (panels A and B) and one containing a mixture of 
WT and variant viruses with a Q136R NA mutation (panel 
C). Proportion of Q136K or Q136R was determined by 
pyrosequencing analysis.
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Eagle’s medium (DMEM)/Ham’s F12/Coon’s medium 
with L-glutamine (SAFC Biosciences) supplemented 
with 2 nM L-glutamine (SAFC Biosciences), 1X Eagle’s 
minimum essential medium (MEM) non-essential amino 
acids (Sigma), 0.06% (v/v) sodium bicarbonate (Sigma), 
0.02 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) buffer solution (Sigma), 2% penicillin–
streptomycin solution (Sigma) and 10% fetal bovine 
serum (SAFC Biosciences). Viruses were cultured in 
MDCK cells in DMEM/Ham’s F12/Coon’s maintenance 
medium with L-glutamine (SAFC Biosciences) supple-
mented with 2 nM L-glutamine (SAFC Biosciences), 1X 
MEM non-essential amino acids (Sigma), 0.06% (v/v) 
sodium bicarbonate (Sigma), 0.02 M HEPES buffer 
solution (Sigma), 2% penicillin-streptomycin solution 
(Sigma), 2 μg/mL fungizone (amphotericin B) (SAFC 
Biosciences) and 4 μg/mL trypsin (Sigma).
Neuraminidase activity and neuraminidase 
inhibition assays
To determine NA activity, viruses were standardised 
to an equivalent haemagglutinin (HA) titre using tur-
key red blood cells, serially diluted (twofold) in assay 
buffer (32.5 mM 2-(N-morpholino)ethanesulfonic acid 
(MES) pH 6.5, 4 mM CaCl2 with 0.1% nonyl phenoxy-
polyethoxylethanol (NP-40)), and then mixed with an 
equal volume (50 μL) of the fluorescence substrate 
2-(4-methylumbelliferyl)-a-D-N-acetylneuraminic acid 
(MUNANA) (0.3 mM) (Sigma) before incubation at 
37 °C for 60 min. The reaction was terminated by the 
addition of 100 μL of stop solution (0.14 M NaOH in 
83% ethanol). Quantification of the fluorescent prod-
uct 4-methylumbelliferone was determined using a 
Fluoroscan Ascent FL (Thermo) with an excitation 
wavelength of 360 nm and an emission wavelength of 
448 nm. Viruses were tested in duplicate in three sepa-
rate assays. The NA activity of the recombinant variant 
viruses was calculated as a relative percentage of the 
NA activity of the recombinant wildtype (WT) virus at 
the same virus dilution.
Viruses were tested for susceptibility to the NAIs 
laninamivir, oseltamivir carboxylate, peramivir, and 
zanamivir, which were kindly provided by Daiichi-
Sankyo, Japan, Hoffman-La Roche Ltd, Switzerland, 
BioCryst Pharmaceuticals Inc., United States (US), and 
GlaxoSmithKline, United Kingdom (UK), respectively. 
To determine the drug concentration required to inhibit 
50% of the NA activity (IC50), 50 μL of virus, diluted 
according to the NA activity assay, was mixed with 
varying concentrations of inhibitor in microtitre plates 
(FluoroNunc plates, Nunc). Final reaction mixture con-
centrations of the NAIs ranged from 0.01 nM to 10,000 
nM. The virus/NAI mix was incubated at room tempera-
ture for 45 min before the addition of 50 μL of MUNANA 
substrate (0.3 mM) and then incubated at 37 °C for 60 
min. The reaction was terminated by addition of 100 μL 
of the stop solution. The data were plotted as the per-
centage of fluorescence activity inhibited against the 
log NAI concentration. IC50 values were calculated using 
the logistic curve fit programme ‘Robosage’ kindly pro-
vided by GlaxoSmithKline, UK.
Reverse transcription-polymerase chain 
reaction, sequencing and pyrosequencing
Reverse transcription-polymerase chain reaction 
(RT-PCR) was conducted using gene specific prim-
ers (sequences available on request) using the 
SuperScript III One-Step RT-PCR System with Platinum 
Taq DNA Polymerase Kit (Life Technologies) accord-
ing to the manufacturer’s instructions. Sequencing 
was conducted using the ABI Prism Dye Terminator 
III Cycle Sequencing Kit (Life Technologies) and ana-
lysed on the ABI 3500XL automated DNA sequencer 
(Life Technologies) and data aligned using the DNAStar 
Lasergene 8 software package. Pyrosequencing to 
determine the relative proportion of a Q136 variant 
in a viral population used the PyroMark ID System 
(QIAGEN). Briefly, 40 µL biotinylated PCR product was 
Figure 2
Thermostability of influenza viruses expressing 
wildtype, Q136R, Q136K, Q136L or Q136H substituted 
neuraminidases
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immobilised on streptavidin-coated sepharose beads 
(QIAGEN), transferred using the PyroMark Vacuum Prep 
Workstation (QIAGEN) into 40 µL of PyroMark Annealing 
Buffer containing pyrosequencing primers and then 
subjected to pyrosequencing reactions using PyroGold 
Reagents (QIAGEN) following the manufacturer’s pro-
tocol. The relative proportion of a Q136 variant in a 
sample was determined using the Allele Quantitation 
application of the PyroMark ID software.
Serial passage experiments in Madin-Darby 
canine kidney epithelial cells and eggs 
Three isolates containing WT (i.e. Q136) and Q136K or 
alternatively WT (Q136) and Q136R were passaged four 
times in either MDCK cells from Queensland Health 
Scientific Services (henceforth referred to as Brisbane 
MDCK cells), MDCK cells from the WHO CC, MDCK-
SIAT1 cells or 11 day-old embryonated hens’ eggs. The 
Brisbane MDCK cells were originally received from ATCC 
(CCL-34) and used at passage level 77 to 90 and, before 
use in the serial viral passage experiments, were grown 
in Opti-MEM with L-glutamine (Thermo Fisher), sup-
plemented with 100x Antibiotic / Antimycotic (Thermo 
Fisher) and 10% fetal bovine serum (Thermo Fisher). 
The MDCK-SIAT1 cells were kindly provided by Professor 
Hans-Dieter Klenk, University of Marburg, Germany, 
and before the serial viral passage study, these cells 
were passaged in the same medium as described pre-
viously for the WHO CC MDCK cells except that it was 
further supplemented with 1 mg/mL G418 sulphate 
(Geneticin, GIBCO, US). Viruses were diluted 1:100 after 
each passage and used for inoculation of the subse-
quent passage. Viruses were cultured in eggs for two 
days at 35 °C, and in cells for up to five days at 35 °C in 
the medium used for the WHO CC MDCK cells described 
previously.
Plasmid construction, site directed mutagenesis 
and reverse genetics
The NA segments from the A(H3N2) virus A/
Wyoming/3/2003 and the A(H1N1)pdm09 virus A/
Auckland/0.5009 were amplified by RT-PCR, digested 
with the restriction enzyme BsaI and ligated into the 
BsmBI digested pHW2000 vector (kindly provided by 
St Jude Children’s Research Hospital, Memphis) using 
the Quick Ligation Kit T4 ligase (New England Biolabs) 
according to the manufacturer’s protocol. Plasmids 
were transformed into One Shot TOP10 Competent 
E. coli Cells (Life Technologies) and positive clones 
were inoculated into 5 mL Fast-Media Ampicillin TB 
(InvivoGen, US) and incubated at 37 °C with shaking at 
225 rpm for 16 hours. Plasmid DNA was then isolated 
using the QIAprep Spin Miniprep Kit (QIAGEN) accord-
ing to the manufacturer’s protocol and eluted into 50 
μL autoclaved water.
Single nucleotide (nt) mutations were introduced into 
the NA plasmids to alter the Q136 codon to residues 
H, K, L, or R using the QuikChange Multi Site Directed 
Figure 3
Haemagglutinin/neuraminidase balance of influenza 
viruses expressing wildtype, Q136R, Q136K, Q136L or 
Q136H neuraminidases following incubation at 4 °C, 37 °C 
and in the absence of epithelial cells (control) 
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Year
A(H1N1)pdm09 A(H3N2)
Isolates 
N 
Q136K 
n (%)
Q136R 
n (%)
Isolates 
N 
Q136K 
n (%)
Q136R 
n (%)
2009 1,068 0 (0.0) 0 (0.0) 117 0 (0.0) 0 (0.0)
2010 1,796 0 (0.0) 0 (0.0) 280 0 (0.0) 0 (0.0)
2011 1,172 9 (0.8) 12 (1.0) 798 1 (0.1) 0 (0.0)
2012 237 1 (0.4) 1 (0.4) 1,620 0 (0.0) 0 (0.0)
2013 960 0 (0.0) 0 (0.0) 668 1 (0.1) 0 (0.0)
2014 1,236 0 (0.0) 0 (0.0) 526 0 (0.0) 0 (0.0)
Total 6,469 10 (0.2%) 13 (0.2) 4,009 2 (<0.1) 0 (0.0)
Table 1
Frequency of Q136K or Q136R variants detected in 
A(H1N1)pdm09 or A(H3N2) surveillance samples in the 
Asia-Pacific region, 2009–2014
The Global Initiative on Sharing Avian Influenza Data (GISAID) 
isolate identity numbers for sequences of selected Q136K and 
Q136R viruses detected in this study are: EPI_ISL_103643, 
172961, 172962, 106853, 106854, 106855, 106856, 106849, 
122566, 106851 and 128664 (www.gisaid.org).
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Mutagenesis Kit (Agilent Technologies) and using 
mutagenesis primers designed according to manu-
facturer’s guidelines and synthesised by GeneWorks 
(Adelaide, Australia). The NA segment was sequenced 
directly from the plasmid as described previously to 
confirm that the desired mutation had been introduced 
and that no additional mutations were present.
Recombinant viruses composed of the NA gene from 
one of the viruses described above, and the remaining 
seven segments from A/Puerto Rico/8/34 (A/PR/8/34 
plasmids kindly provided by Dr Robert Webster, St. 
Jude Children’s Research Hospital, Memphis) were gen-
erated by reverse genetics. All eight plasmids were 
transfected into a co-culture of 293T and MDCK cells as 
previously described [21]. Rescued viruses were subse-
quently cultured in MDCK cells in maintenance media 
described above.
Thermostability and neuraminidase cleavage 
from A549 cells
The thermostability of the NA was determined by sub-
jecting viruses to a range of temperatures and then 
determining the amount of residual NA activity as a 
percentage of the NA activity of the virus at 37 °C. The 
lower temperatures (38 and 41 °C) were physiologically 
relevant, while the higher temperatures (47 and 54 °C) 
provided information about protein stability. Virus 
was incubated at 37, 38, 41, 47 and 54 °C for 15 min 
using the gradient function on a thermocycler (Bio-Rad 
Laboratories) and the NA activity of each virus calcu-
lated based on the mean of triplicate assays.
NA cleavage efficiency was characterised by the bind-
ing and elution of WT and mutant virus to A549 ade-
nocarcinomic human alveolar epithelial cells (ATCC) 
following a previously published protocol [22]. A549 
cells were grown in the growth medium described pre-
viously. Virus with a known HA titre was allowed to bind 
to human epithelial cells at 4 °C for 30 min and the HA 
titre of the supernatant determined. To assess the NA 
efficiency, the virus/cells (previously incubated at 4 °C) 
were then incubated at 37 °C to provide an opportunity 
for NA to cleave the HA and release the virus from cells. 
The comparative HA titre of the cell supernatant, with-
out cells (control) compared with ‘after binding’ (4 °C) 
and ‘after elution’ (37 °C) incubations, was used to 
indicate the efficiency of NA cleavage.
Results
Q136K and Q136R variants detected during 
surveillance testing
A total of 6,469 A(H1N1)pdm09 and 4,009 A(H3N2) 
virus isolates from the Asia-Pacific region were tested 
at the WHOCC for their susceptibility to the NAIs from 
2009 to 2014. Prior to 2011, all A(H1N1)pdm09 and 
A(H3N2) virus isolates demonstrated normal inhibi-
tion to zanamivir. However, in 2011, 21 of 1,172 (1.1%) 
A(H1N1)pdm09 isolates tested showed either reduced- 
or highly reduced-inhibition to zanamivir due to a 
substitution of the Q136 residue in the NA to either K 
(n = 9) or R (n = 12) (Table 1). In 2012, two of 237 (0.8%) 
A(H1N1)pdm09 virus isolates were also considerably 
less inhibited by zanamivir and similarly contained 
either a Q136K or Q136R NA substitution. After 2012, 
no more A(H1N1)pdm09 virus isolates with Q136K or 
Q136R were detected. With regard to A(H3N2), during 
the period from 2011 to 2014, zanamivir inhibition was 
found to be reduced in two virus isolates (one in 2011 
and one in 2013) due to a Q136K NA substitution (Table 
1).
Only one of the Q136K A(H1N1)pdm09 isolates and 
three Q136R isolates appeared to be pure viral popu-
lations following pyrosequencing analysis, while all of 
the others were detected as mixed viral populations, 
with proportions of variant virus ranging from 47 to 
Subtype NA mutation NA activity (% of WT)
IC50 (nM) ± SD (Fold difference of IC50 compared with WT)
Zanamivir Oseltamivir Peramivir Laninamivir
A(H1N1)pdm09
None (WT) – 0.2 ± 0.0 (–) 0.3 ± 0.1 (–) 0.1 ± 0.0 (–) 0.2 ± 0.0 (–)
Q136L 54.2 ± 3.6 6.3 ± 2.0 (32) 3.6 ± 0.6 (12) 0.5 ± 0.3 (5) 0.8 ± 0.1 (4)
Q136H 98.6 ± 0.8 0.2 ± 0.0 (1) 0.2 ± 0.1 (1) 0.1 ± 0.0 (1) 0.2 ± 0.0 (1)
Q136R 34.2 ± 0.8 161.9 ± 35.0 (810) 0.2 ± 0.0 (1) 68.2 ± 16.8 (682) 131.8 ± 30.7 (659) 
Q136K 32.9 ± 1.6 117.7 ± 11.7 (589) 0.3 ± 0.0 (1) 34.3 ± 3.7 (343) 25.5 ± 6.0 (126) 
A(H3N2)
None (WT) – 1.3 ± 0.3 (–) 0.5 ± 0.1 (–) 0.3 ± 0.0 (–) 1.2 ± 0.1 (–)
Q136L 37.3 ± 1.3 12.8 ± 2.5 (10) 6.5 ± 1.2 (13) 0.9 ± 0.3 (3) 1.3 ± 0.4 (1)
Q136H 109.3 ± 1.0 0.8 ± 0.2 (1) 0.2 ± 0.1 (1) 0.2 ± 0.1 (1) 1.0 ± 0.2 (1)
Q136R 82.5 ± 3.6 3.0 ± 0.7 (2) 1.4 ± 0.2 (3) 0.8 ± 0.0 (3) 1.1 ± 0.0 (1)
Q136K 43.2 ± 3.1 12.3 ± 2.4 (10) 6.6 ± 1.4 (13) 0.9 ± 0.3 (3) 1.6 ± 0.2 (1)
Table 2
Neuraminidase (NA) activity and NA inhibitor susceptibility of reverse genetics derived Q136 variants
IC50: drug concentration required to inhibit 50% of the NA activity; SD: standard deviation; WT: wildtype.
Figures in bold indicate a 10-fold or greater increase in IC50 compared with the respective WT virus. Mean ± SD are derived from three separate 
experiments.
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80% for the Q136K isolates, and three to 94% in the 
Q136R isolates. As a result of the mixed viral popula-
tions, the zanamivir IC50 values of the different isolates 
differed markedly from each other, with the Q136K 
isolates ranging from 1.9 to 250 nM, and the Q136R 
isolates ranging from 2.1 to 92 nM. Neither the Q136K 
nor Q136R isolates had an increased oseltamivir IC50, 
although they did have an increased peramivir and lan-
inamivir IC50 (data not shown).
Following detection of the Q136K or Q136R variants in 
MDCK isolates, it was necessary to determine whether 
viruses with these substitutions were present in the 
respective original clinical specimens. Of the 25 virus 
isolates where a Q136K or Q136R variant was detected, 
16 clinical specimens were available for analysis. 
Sanger sequencing or pyrosequencing failed to detect 
the presence of the variants in any of the clinical speci-
mens tested, even as a minor proportion of the viral 
population. Clonal analysis of one of the virus samples 
was conducted but again failed to detect the presence 
of the variant in 92 clones analysed. These data dem-
onstrated that the Q136K or Q136R variants viruses 
were either below the level of detection of the assays 
or were not present in the specimen but spontaneously 
generated during culture. Given these findings, it was 
clear that these viruses were being positively selected 
during MDCK cell culture. All of the Q136K or Q136R iso-
lates had been passaged between two and four times in 
MDCK cells before analysis. Two Q136R A(H1N1)pdm09 
isolates which contained > 80% Q136R had only been 
passaged twice in MDCK cells. Seventeen (68%) of the 
25 Q136K or Q136R isolates detected at the WHO CC, 
had initially been passaged and submitted to the WHO 
CC by a single laboratory in Brisbane, Australia. This 
was a disproportionately high number of viruses with 
a mutation at Q136 given that during the 2009 to 2014 
period this laboratory submitted 24.3% (2,552/10,478) 
of all of the viruses tested at the WHOCC.
Serial passage of Q136K and Q136R A(H1N1)
pdm09 viruses in cell and egg culture
To better understand whether the MDCK cells used by 
the Brisbane laboratory were more selective for the 
Q136K or Q136R A(H1N1)pdm09 variants than other 
cell lines, two isolates containing NA 136 Q/K mixtures 
(named A/Brisbane/345/2011 and A/Brisbane/70/2011) 
and one isolate with a NA 136 Q/R mixture (A/
Perth/130/2011) were passaged four times in either 
Brisbane MDCK cells, WHOCC MDCK cells, MDCK-
SIAT1 cells or hens eggs. Passage in the Brisbane 
MDCK cells either maintained or increased the pro-
portion of Q136K or Q136R viruses in the viral popu-
lation (Figure 1). This positive selection for the Q136K 
variant was also observed following passage of the A/
Brisbane/345/2011 isolate in the WHOCC MDCK cells, 
but was not seen with the other two isolates, where 
passage in WHOCC MDCK cells resulted in the gradual 
loss of the Q136K or Q136R variant. The MDCK-SIAT1 
cells consistently selected against the Q136K or Q136R 
variants, with the proportion of each variant gradually 
decreasing after serial passage (Figure 1). The largest 
change in mixture proportion was seen following egg 
passage, which showed that growth of the variants 
were not well supported in embryonated eggs and were 
rapidly selected against, such that after a single pas-
sage in eggs the Q136K and Q136R viruses were unde-
tectable in two of the isolates, and accounted for < 10% 
of the viral population in the third isolate (Figure 1).
Neuraminidase activity and neuraminidase 
inhibitor susceptibility of reverse genetics 
derived Q136K, R, L and H variants
Examination (in 2014) of human and avian N1 and N2 
sequences from the public sequence databases Global 
Initiative on Sharing Avian Influenza Data (GISAID) and 
GenBank revealed not only the Q136R and Q136K sub-
stitutions, but also Q136L and Q136H, present in a small 
number (less than 1%) of sequences from A(H3N2), 
A(H1N1) and A(H5N1) virus isolates. Site directed 
mutagenesis and reverse genetics were used to bet-
ter investigate the phenotypic effect of the Q136K, 
Q136R, Q136L and Q136H substitutions in the NAs from 
A(H1N1)pdm09 and A(H3N2) viruses. 7:1 reassortants 
containing either the N1 or N2 WT NA (no mutations) or 
variant NA (Q136K, R, L or H) on a PR/8 backbone were 
successfully generated by reverse genetics.
For N1 reassortants, the Q136H mutant retained full NA 
activity, while the Q136R, Q136K and Q136L mutants 
had between 33 and 54% of the WT NA activity (Table 
2). For the same mutations in the N2 NA, the Q136H 
substitution also had no effect on NA activity, whereas 
the Q136R substitution caused a minor reduction in NA 
activity (82% activity of WT), and the Q136K and Q136L 
substitutions caused large reductions in NA activity 
(40% activity of WT) (Table 2).
Analysis of the N1 reassortants for NAI susceptibil-
ity showed that the Q136H substitution had no effect, 
whereas the Q136L mutant demonstrated a moder-
ate 32-fold increase in zanamivir IC50 and a minor 
4- to 12-fold increase in oseltamivir, peramivir and 
laninamivir IC50 compared with the respective WT. In 
comparison, the Q136R substitution caused a 659- to 
810-fold increase in zanamivir, peramivir and laninami-
vir IC50 compared with WT, while the Q136K substitution 
caused a 126- to 589-fold increase against the same 
NAIs (Table 2). Both the Q136K and Q136R substitu-
tions had no effect on oseltamivir susceptibility. 
The large effect of the Q136R and Q136K substitutions 
observed in the N1 NA was not observed in the N2 NA. 
Q136R caused only a minor (two- to threefold) change 
in oseltamivir, peramivir and zanamivir IC50. A Q136L 
or a Q136K substitution caused a moderate 10- to 
13-fold increase in zanamivir and oseltamivir IC50 and 
a threefold increase in peramivir IC50 but no change in 
laninamivir sensitivity compared with the WT. Q136H 
in N2 had no effect on NAI sensitivity, similar to that 
observed in the N1 NAs (Table 2).
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Viral function of reverse genetics derived 
Q136K, R, L and H variants
The thermostability and HA/NA balance of the reassor-
tant variant viruses were determined. The Q136L and 
Q136H N1 variants retained high NA activity across the 
38 °C to 54 °C temperature range, equivalent to that of 
the WT virus. However the N1 reassortants with Q136K 
and Q136R mutations showed a substantial loss of activ-
ity at 54 °C (67% and 22% remaining activity compared 
to 37 °C respectively) (Figure 2A). The N2 reassortant 
WT had some loss of activity at 54 °C (30% remaining 
activity), as did the NAs with Q136R and Q136H muta-
tions (8–21% remaining activity), while the NAs with 
Q136K and Q136L mutations maintained high activity 
(> 80%) across the entire temperature range (Figure 2B). 
All N1 and N2 reassortant viruses contained the PR/8 
HA and all showed good cell binding at 4 °C, as indi-
cated by low viral titres in the supernatant. After incu-
bation at 37 °C, the N1 WT reassortant and the Q136L 
variant showed full restoration of HA titre, demon-
strating an active NA enzyme, whereas the Q136K 
and Q136R variants had only partial restoration of HA 
titre, suggesting that the NA activity was insufficient 
to cleave all bound virus from the cells (Figure 3A). All 
of the N2 reassortants, with the exception of Q136K, 
showed full restoration of HA titre following incubation 
at 37 °C (Figure 3B).
Discussion
In this study we describe the detection of A(H1N1)
pdm09 influenza virus isolates, and to a lesser extent 
A(H3N2) viruses, with amino acid substitutions at the 
Q136 NA residue that reduce zanamivir, peramivir and 
laninamivir susceptibility. Surveillance data show that 
the Q136K and Q136R substitutions occurred sporadi-
cally in A(H1N1)pdm09 cultured isolates, with periods 
such as 2011 where a relatively high detection rate was 
observed, compared with other years where they were 
absent. Importantly, in all cases, the residue substitu-
tion that was present in the isolate, was not detected 
in the virus from the clinical specimen demonstrating 
that the mutation was either arising, or being selected 
for, during MDCK cell culture passage. Because the 
‘gold-standard’ for laboratory assessment of NAI sus-
ceptibility is the phenotypic NA inhibition assay, which 
requires a cell culture isolate for testing, there is con-
cern that viruses such as these can be reported as 
being ‘resistant’ when in fact the virus that came from 
the patient was sensitive. In addition, the process of 
cell culture may also select against a resistant virus, 
meaning that a variant virus is not detected when it 
was present in the clinical specimen. Misdiagnosis can 
have an impact on the therapies being used in patient 
management and may unnecessarily result in therapy 
being stopped, modified or inappropriately continued. 
In addition to the Q136K/R variants described here, 
there are many other NA mutations that alter NAI sus-
ceptibility and also appear to be selected during MDCK 
cell culture [19,23]. Interestingly these seem to be 
increasingly reported for influenza B viruses [23-25]. 
Therefore sequence analysis of the influenza viruses in 
the original specimen remains important when labora-
tories detect mutations in cultured isolates.
While conventional MDCK cells selected for the Q136K 
and Q136R A(H1N1)pdm09 variants, their growth was 
not supported in eggs, with a single passage resulting 
in the near complete loss of the variant virus. MDCK-
SIAT1 cells also did not appear to give selective growth 
advantage to the Q136 variants. MDCK-SIAT1 cells have 
enhanced binding due to an increased concentration of 
α2,6-linked sialic acids on the MDCK cell surface [26], 
which may mean that viruses with reduced NA activity, 
such as the Q136K/R variants, have reduced replication 
in this cell line, possibly explaining the difference with 
the conventional MDCK cell lines. If clinical samples are 
available in the future that have been shown to result 
in MDCK isolates with Q136K/R mutations, it would be 
useful to test whether primary isolation into MDCK-
SIAT1 or human bronchial epithelial cells prevents this 
initial selection of the variant virus.
Although the Q136K and Q136R variants detected here 
were all cell culture derived variants, other studies 
have reported mutations at Q136 that were detected 
in viruses from clinical specimens. The Q136K muta-
tion was detected in an A(H3N2) virus, together with 
an E119V NA mutation, in a patient who had previously 
undergone a bone marrow transplant, following a treat-
ment course of both inhaled and intravenous zanamivir 
and oseltamivir [27]. Mutations at Q136 have also been 
detected in ferrets infected with influenza A(H5N1). 
The Q136L variant was detected in the nasal wash of 
a zanamivir treated ferret infected with an A(H5N1) 
virus [28], while a Q136H mutation was detected in an 
A(H5N1) virus from a ferret not being treated with an 
antiviral [29]. These reports demonstrate that viruses 
with these mutations have the potential to infect or 
replicate in vivo both in the presence or absence of 
zanamivir pressure.
The zanamivir concentration in sputum 12 hours post-
inhalation has been reported to be between 159 and 
4,315 nM [30]. Therefore, while the correlation between 
the drug concentration in sputum and the drug concen-
tration at the site of viral replication is not clear, it is 
anticipated that only the Q136K and Q136R mutations 
in the A(H1N1)pdm09 virus may potentially impact the 
clinical effectiveness of zanamivir. The Q136L mutation 
in both N1 and N2 NAs and Q136K in N2 NA caused mild 
increases in zanamivir and oseltamivir IC50, which are 
expected to be below the concentrations present at the 
sites of replication in treated individuals [30,31].
An evaluation of the ability of the Q136K and Q136R 
A(H1N1)pdm09 variants to replicate and transmit in 
animal models will provide useful insights into the 
potential risk that these viruses may pose to public 
health. Where possible these future studies would 
benefit from using Q136K and Q136R variants that were 
naturally occurring, rather than cell culture derived or 
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generated by reverse genetics. One limitation of this 
study is that the N1 and N2 NAs with Q136 substitutions 
were assessed in 1:7 reassortant viruses generated by 
reverse genetics on a PR/8 backbone, therefore there 
is potential that the HA/NA balance between the vari-
ant NA molecules and the HA from PR/8 may be differ-
ent from that seen in the ‘natural’ isolate. The in vitro 
assays showed that as a result of the Q136K mutation 
the N1 reassortant had a moderate loss in NA activity 
and thermostability. A reduction in NA enzyme activity 
and surface expression due to the Q136K NA mutation 
has been previously reported [32,33]. Pizzorno et al. 
[33] also demonstrated that an A(H1N1)pdm09 Q136K 
variant had compromised replication compared with 
a WT virus in mice, while in a ferret model the vari-
ant was able to transmit between contact ferrets, but 
at slower rate than for the WT virus. However, a study 
in guinea pigs found that the Q136K variant did not 
transmit between animals [32]. Taken together, these 
studies indicate that the replication and transmissi-
bility of the Q136K variant in the A(H1N1)pdm09 virus 
appears to be compromised and therefore is unlikely 
to circulate through the human population. However, 
compensatory mutations in the NA or other genes that 
may occur in the A(H1N1)pdm09 virus in the future may 
buffer the compromising effect of the Q136K muta-
tion and improve overall replication and transmissibil-
ity of the variant, in a manner similar to that seen for 
the H275Y mutation [7,34]. To date there has been no 
evaluation of the in vivo fitness of the Q136R A(H1N1)
pdm09 variant.
In this study we have highlighted the challenges that 
cell culture derived mutations, such as Q136K and 
Q136R, can pose to the analysis and interpretation of 
viruses for NAI susceptibility. This further reaffirms the 
need to sequence viruses from the clinical specimens 
of any isolate that shows reduced susceptibility in a 
phenotypic NA inhibition assay to avoid misdiagnosis 
and any unnecessary change in patient management 
with respect to the use of antivirals. Our findings high-
light the effect of mutations at the Q136 residue of N1 
viruses on laninamivir, peramivir or zanamivir suscep-
tibility, and therefore close monitoring of viruses for 
these mutations in patients being treated with these 
antivirals is important.
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